黄精多糖对糖尿病模型小鼠糖代谢的影响

Effect of polygonati polysaccharide on glucose metabolism in diabetic mice

目的:探讨中药黄精提取物黄精多糖对实验性糖尿病鼠的降糖作用及对糖化血红蛋白的调节。方法:实验于2004-03/06在中南大学湘雅二医院实验动物室完成。选取10～12周BALB/C小鼠30只,随机分为模型组、糖脉康组、黄精多糖组,10只/组。黄精多糖由中南大学湘雅二医院临床药学研究室提供(每毫升相当于黄精生药10g)。糖脉康为中国中医研究院中汇制药公司产品(批号030905)。各组小鼠均建立实验性糖尿病动物模型,腹腔注射链脲佐菌素4mL/(kg·d),连续5d。造模完成后,糖脉康组将12.5g/(kg·d)糖脉康加入1mL生理盐水溶解,分两次灌胃给予;黄精多糖组将4mL/(kg·d)的黄精多糖溶入1mL生理盐水,分两次灌胃给予;模型组只喂等量生理盐水。各组给药时间均为8周。分别于实验前及建立糖尿病模型禁食6h后,剪尾测定各组小鼠血糖含量。最后用取小鼠眶动脉血,血糖变化以葡萄糖氯化酶法检测,糖化血红蛋白测定采用柱层析法,血浆胰岛素和C肽测定采用放射免疫法。结果:实验纳入30只小鼠,全部进入结果分析。①各组造模前后血糖变化:与造模前比较,造模后模型组、糖脉康组、黄精多糖组血糖均显著升高犤(5.45±1.02),(8.95±2.31);(4.97±0.99),(8.39±1.81);(6.13±1.36),(9.17±1.89)mmol/L;P均<0.01犦;造模后各组间基本相似(P>0.05)。②各组实验前后血糖检测结果:与实验前比较,实验后糖脉康组和黄精多糖组均显著降低犤(8.39±1.81),(6.77±1.34);(9.17±1.89),(6.43±1.22)mmol/L;t=3.264～2.791,P均<0.05犦,模型组基本无变化。③实验后各组血清糖化血红蛋白情况:与模型组比较,黄精多糖组显著下降犤(3.37±0.33),(1.61±0.29)%,t=6.148～4.395,P<0.01犦,糖脉康组基本无变化。④实验后各组血浆胰岛素及血浆C肽情况:与模型组比较,糖脉康组和黄精多糖组均显著升高犤(5.67±2.49),(10.13±5.82),(24.64±7.31)U/L,t=6.148,P<0.05;(27.6±10.52),(56.54±21.87),(113.79±23.45)pmmol/L,t=4.395,P<0.01犦。结论:黄精多糖可显著降低实验性糖尿病鼠血糖和血清糖化血红蛋白浓度,并明显升高血浆胰岛素及C肽水平,表明黄精多糖具有调节糖代谢和治疗实验性糖尿病的作用。

AIM： To investigate the effects of the siberian solomonseal rhizome extract polygonati polysaccharide in decreasing glucose and regulating glycosylated hemoglobin of experimental diabetic mice. METHODS： The experiment was performed in the animal room of the Second Xiangya Hospital of Central South University between March and June 2004. Thirty 10 to 12-week-old BALB/C mice were randomly divided into model group （n=10）, tangmaikang group （n=10） and pelygonati polysaccharide group （n=10）. Polygonati pelysaccharide was provided by the Research Room of Clinical Pharmacology, the Second Xiangya Hospital of Central South University （1 mL equals to 10 g crude drug of pelygonati pelysaccharide）. Tangmaikang was produced by the Zhonghui Pharmaceutical Company of China Academy of Traditional Chinese Medicine （No. 030905）. All the mice were made into experimental diabetic models by means of intraperitoneal injection of streptozotocin （4 mL/kg per day） for 4 continuous days. After model establishment, mice in the tangmaikang group were treated with gastric perfusion of tangmaikang （12.5 g/kg per day）, which was dissolved in 1 mL saline and given by twice, those in the pelygonati polysaccharide group were treated with gastric perfusion of polygonati polysaccharide （4 mL/kg per day）, which was dissolved in 1 mL saline and given by twice, and those in the model group were only fed with saline of the same volume. All the mice were administrated for 8 weeks. Before experiment and after the diabetic models were fasted for 6 hours, the tails were cut to determine the content of glucose in each group, and then the arterial blood of orbit was drawn, the changes of blood glucose was detected with the method of glucoseoxidase, the level of glycosylated hemoglobin was determined with chromatography respectively, and the levels of insulin and C peptide in plasma were detected with radioimmunoassy. RESULTS： All the 30 mice were involved in the analysis of results. ① The changes of blood glucose before and after model establishment in each group： Compared with before model establishment, the levels of blood glucose in the model group, tangmaikang group and pelygonati polysaccharide group were all significantly increased after model establishment [（5.45±1.02）, （8.95±931）; （4.97±0.99）, （8.39±1.81）; （6.13±1.36）,（9.17±1.89） mmol/L; P 〈 0.01], and there were insignificant differences among the groups after model establishment （P 〉 0.05）. ② The results of blood glucose before and after experiment in each group： Compared with before experiment, the levels of blood glucose were remarkably decreased after experiment in the tangmaikang group and polygonati pelysaccharide group [（8.39±1.81）, （6.77±1.34）; （9.17±1.89）, （6.43±1.22） mmol/L; t=3.264 to 2.791, P 〈 0.05], and there was almost no change in the model group. ③ The serum level of glycosylated hemoglobin after experiment in each group： Compared with the model group, it was significantly increased in the polygonati polysaccharide group [（3.37±0.33）, （1.61±0.29）%, t=6.148 to 4.395, P 〈 0.01], and there was no obvious change in the tangmaikang group. ④ The levels of insulin and C peptide in plasma after experiment in each group： Compared with the model group, those were significantly increased in the tangmaikang group and pelygonati polysaecharide group [（5.67±9.49）, （10.13±5.82）, （24.64±7.31） U/L, t=6.148, P〈 0.05; （27.6±10.52）, （56.54±21.87）, （113.79±23.45） pmmol/L, t=4.395, P 〈 0.01]. CONCLUSION： Polygonati pelysaccharide can significantly decrease the concentrations of blood glucose and serum glycosylated hemoglobin of experimental diabetic mice, and obviously increase the levels of insulin and C peptide in plasma, it is indicated that pelygonati pelysaccharide hasthe effects of regulating glucose metabolism and treating experimental diabetes mellitus.